253 related articles for article (PubMed ID: 26827165)
1. Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.
Huang Y; DiazGranados C; Janes H; Huang Y; deCamp AC; Metch B; Grant S; Sanchez B; Phogat S; Koutsoukos M; Kanesa-Thasan N; Bourguignon P; Collard A; Buchbinder S; Tomaras GD; McElrath J; Gray G; Kublin JG; Corey L; Gilbert PB
Curr Opin Virol; 2016 Apr; 17():57-65. PubMed ID: 26827165
[TBL] [Abstract][Full Text] [Related]
2. Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.
Huang Y; Gilbert PB; Fu R; Janes H
Biostatistics; 2017 Apr; 18(2):230-243. PubMed ID: 27649715
[TBL] [Abstract][Full Text] [Related]
3. HIV Vaccine Efficacy Trials: RV144 and Beyond.
Heger E; Schuetz A; Vasan S
Adv Exp Med Biol; 2018; 1075():3-30. PubMed ID: 30030787
[TBL] [Abstract][Full Text] [Related]
4. Statistical evaluation of HIV vaccines in early clinical trials.
Moodie Z; Rossini AJ; Hudgens MG; Gilbert PB; Self SG; Russell ND
Contemp Clin Trials; 2006 Apr; 27(2):147-60. PubMed ID: 16426900
[TBL] [Abstract][Full Text] [Related]
5. Support for the RV144 HIV vaccine trial.
Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
[No Abstract] [Full Text] [Related]
6. Outstanding questions on HIV vaccine trial.
Jefferys R; Harrington M
Science; 2004 Jul; 305(5681):180; author reply 180. PubMed ID: 15247456
[No Abstract] [Full Text] [Related]
7. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.
Rolland M; Gilbert P
AIDS Res Hum Retroviruses; 2012 Apr; 28(4):400-4. PubMed ID: 21902593
[TBL] [Abstract][Full Text] [Related]
8. Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect.
Lhomme E; Hejblum BP; Lacabaratz C; Wiedemann A; Lelièvre JD; Levy Y; Thiébaut R; Richert L
J Immunol Methods; 2020 Feb; 477():112711. PubMed ID: 31809708
[TBL] [Abstract][Full Text] [Related]
9. International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.
Li D; Forrest BD; Li Z; Xue P; Hanson CV; Duan S; Cheng H; Li M; Wang CY; Koff WC
Asian Pac J Allergy Immunol; 1997 Jun; 15(2):105-13. PubMed ID: 9346275
[TBL] [Abstract][Full Text] [Related]
10. HIV vaccine efficacy trials: towards the future of HIV prevention.
Kim D; Elizaga M; Duerr A
Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
[TBL] [Abstract][Full Text] [Related]
11. Use of placebos in Phase 1 preventive HIV vaccine clinical trials.
Huang Y; Karuna ST; Janes H; Frahm N; Nason M; Edlefsen PT; Kublin JG; Corey L; McElrath MJ; Gilbert PB
Vaccine; 2015 Feb; 33(6):749-52. PubMed ID: 25454855
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic vaccine trails in Thailand.
Churdboonchart V
J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
[TBL] [Abstract][Full Text] [Related]
13. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 vaccines and adaptive trial designs.
Corey L; Nabel GJ; Dieffenbach C; Gilbert P; Haynes BF; Johnston M; Kublin J; Lane HC; Pantaleo G; Picker LJ; Fauci AS
Sci Transl Med; 2011 Apr; 3(79):79ps13. PubMed ID: 21508308
[TBL] [Abstract][Full Text] [Related]
15. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
16. A shot at AIDS.
Koff WC
Curr Opin Biotechnol; 2016 Dec; 42():147-151. PubMed ID: 27153215
[TBL] [Abstract][Full Text] [Related]
17. Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA
Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576
[No Abstract] [Full Text] [Related]
18. New clinical trial designs for HIV vaccine evaluation.
Moodie Z; Janes H; Huang Y
Curr Opin HIV AIDS; 2013 Sep; 8(5):437-42. PubMed ID: 23872613
[TBL] [Abstract][Full Text] [Related]
19. [HIV-1 vaccination--is there hope?].
Speck RF; Brander C; Kündig TM
Ther Umsch; 2005 Oct; 62(10):695-702. PubMed ID: 16277037
[TBL] [Abstract][Full Text] [Related]
20. First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.
Choi E; Michalski CJ; Choo SH; Kim GN; Banasikowska E; Lee S; Wu K; An HY; Mills A; Schneider S; Bredeek UF; Coulston DR; Ding S; Finzi A; Tian M; Klein K; Arts EJ; Mann JF; Gao Y; Kang CY
Retrovirology; 2016 Nov; 13(1):82. PubMed ID: 27894306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
